Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaya HoldingsKAYS +42.86% ROC (Joel Greenblatt) % is -98,658.46% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, Kaya Holdings ranks worse than 98.78% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kaya Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -98,658.46%.
The historical rank and industry rank for Kaya Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
KAYS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14984.38 Med: -508.13 Max: 1862.77
Current: -14984.38
During the past 12 years, Kaya Holdings's highest ROC (Joel Greenblatt) % was 1862.77%. The lowest was -14984.38%. And the median was -508.13%.
KAYS's ROC (Joel Greenblatt) % is ranked worse than 98.78% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs KAYS: -14984.38
Kaya Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Kaya Holdings (OTCPK:KAYS) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Kaya Holdings ROC (Joel Greenblatt) % Related Terms
Kaya Holdings ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Kaya Holdings's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAYS vs APUS, IGPK, BIOE: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kaya Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaya Holdings ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaya Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Kaya Holdings's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Sep. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -98,658.46% mean?
Kaya Holdings (KAYS) has a ROC (Joel Greenblatt) % of -98,658.46% as of Sep. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kaya Holdings and its competitors. According to the industry distribution chart, Kaya Holdings ranks #971 out of 983 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Kaya Holdings' ROC (Joel Greenblatt) % too high?
Kaya Holdings' current ROC (Joel Greenblatt) % is -98,658.46%. Based on the distribution chart, Kaya Holdings ranks #971 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Kaya Holdings' ROC (Joel Greenblatt) % compare to APUS and IGPK?
According to the Drug Manufacturers industry distribution chart, Kaya Holdings ranks #971 out of 983 companies for ROC (Joel Greenblatt) %. This places Kaya Holdings in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Kaya Holdings and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaya Holdings's current ROC (Joel Greenblatt) % is -98,658.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaya Holdings stock overvalued right now?
Kaya Holdings (KAYS) has a current ROC (Joel Greenblatt) % of -98,658.46%. The current ROC (Joel Greenblatt) % is -98,658.46%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Kaya Holdings (KAYS), the current ROC (Joel Greenblatt) % is -98,658.46% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kaya Holdings Inc is a holding company. It is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. The company own and operate a medical cannabis dispensary in the United States. Its has produced, distributed, and/or sold a full range of premium cannabis products including flower, oils, vape cartridges and cannabis infused confections, baked goods and beverages through a fully integrated group of subsidiaries and companies supporting distinctive brands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAYS has been successfully added to your 
